In Brief: Amgen
Executive Summary
Company settles securities fraud lawsuit against subsidiary Synergen for $17 mil., Seattle law firm of Tousley Brain announced Feb. 18. Payment will go to a limited partnership group, organized by Pain Webber, which invested over $52 mil. in Synergen in four installments between February 1991 and February 1994. The suite alleged that Synergen misrepresented animal and Phase II data for its sepsis treatment Antril and withheld negative pivotal trial results until a capital call was completed. Amgen acquired Synergen in December 1994...